Rising Incidence With Modest Survival Improvement in Salivary Duct Carcinoma: A Population-Based Study in the United States, 2000-2022.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42596652.
- Also identified by DOI 10.1002/hed.70425.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with limited population-based data. Incidence trends and survival outcomes were analyzed using the Surveillance, Epidemiology, and End Results database. A total of 955 cases were identified. The age-adjusted incidence rate increased from 0.158 in 2000 to 1.18 in 2022 (average annual percent change, 10.38%; p < 0.001), accelerating after 2012. Increases were more pronounced among females, older patients, regional-stage disease, and tumors > 2 cm. The 5-year disease-specific survival (DSS) and overall survival were 60.6% and 51.2%, respectively. Advanced age, non-parotid site, larger tumor size, lymph node metastasis, advanced stage, and non-surgical management were independent predictors of worse DSS. Patients diagnosed in 2013-2022 showed better DSS compared with those in 2004-2012 (64.7% vs. 52.0%, p = 0.048). SDC incidence has increased rapidly, possibly reflecting improved diagnostic recognition and reclassification, with only modest survival improvement over the past decade.